sector-health
AUDIT: BioAge Labs
BioAge Labs' $115M pivot to NLRP3 inhibitor BGE-102 masks the biological debt of aging. An audit of the STRIDES trial failure and GLP-1 sarcopenic tax.
sector-health
BioAge Labs' $115M pivot to NLRP3 inhibitor BGE-102 masks the biological debt of aging. An audit of the STRIDES trial failure and GLP-1 sarcopenic tax.
Biological Payday Loan
BioAge's $115M offering isn't a cure; it's a payday loan against rotting cells. They aren't stopping aging, just cutting the wire to your biological alarm.